Novocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the FDA. The PMA application for LUNAR was submitted with a filing date of December 15, 2023, and is now under substantive review by the FDA. Novocure expects to receive a
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles